Europe's regulator has recommended Amgen’s biosimilar Humira, paving the way for a cheaper ... marketing authorisations under two names – Amgevita and Solymbic. Following the positive opinion ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available ...

European regulators have backed a new Humira biosimilar for approval ... the pricing of Humira biosimilars from Sandoz, Amgen (Amgevita and Solymbi), Boehringer Ingelheim (Cyltezo), Samsung ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira ... of its U.S. biosimilar threat. The anti-inflammatory injection, also known as adalimumab ...